Market Signal Briefing

The project announced that its NEXUS chain is now live with LayerZero, linking it to more than 145 supported networks, including popular ecosystems such as Solana, Ethereum, and Base.

October 09, 2025 08:00 ET

 | Source:

Orchestra BioMed Holdings, Inc.

Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration to develop and commercialize AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annuallyAVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients NEW HOPE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced a data summary supporting the transformative potential of Atrioventricular Interval Modulation (“AVIM”) Therapy in the management of hypertensive heart disease will be presented in a keynote talk at the Georgia Innovation Summit in Tbilisi, Georgia on October 10, 2025. The presentation, to be delivered by Avi Fischer, MD, Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed, will showcase AVIM Therapy as a novel, device-based therapeutic approach targeting hypertensive heart disease progression and its potential to redefine standards of care.

Dr. Fischer commented, “This keynote presentation reflects the growing global recognition of AVIM Therapy as a novel, device-based therapy, poised to reshape the future of hypertension care. Hypertension is the principal driver of diastolic dysfunction, which accelerates the development of heart failure. Despite widespread use of antihypertensive therapies, many patients continue to progress along the disease pathway, underscoring the importance of novel therapeutic approaches. The collective body of AVIM Therapy clinical data demonstrates its potential to directly modulate the progression of hypertensive heart disease, offering the potential to intervene earlier in the course of the disease to improve long-term outcomes, transform patient care, and ultimately create lasting value for all stakeholders.”

The keynote presentation will provide a comprehensive overview of clinical and mechanistic AVIM Therapy results from pilot and long-term follow-up studies, highlighting the therapy’s consistent favorable clinical impact on blood pressure and cardiac function:

Immediate, substantial, and sustained blood pressure reduction MODERATO I pilot study: 24-hour ambulatory systolic blood pressure (“aSBP”) reduced by 11.6 mmHg at 1 day and 10.1 mmHg at 3 monthsMODERATO II pilot study: 24-hour aSBP reduced by 15.6 mmHg at 1 day and 11.1 mmHg at 6 months, as well as an office systolic blood pressure reduction of 17.5 mmHg at 24 months Favorable impact on cardiac hemodynamics after 24 months of treatment (MODERATO I) Significant reductions in heart rate and end-diastolic volumeNo significant changes in end-systolic volume or ejection fraction, supporting safety Improvement in echocardiographic measures of diastolic function (MODERATO II) Significant increases in e’ and E/A ratio, indicating improved myocardial relaxation and diastolic compliance Potential to halt hypertensive heart disease progression Long-term follow-up demonstrates sustained blood pressure reduction with reversibility of effect and absence of rebound hypertension upon deactivationFavorable effects were reproducible after a 7-day washout period followed by reactivation, underscoring durability and reliability About Orchestra BioMed

Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM Therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About AVIM Therapy

AVIM Therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM Therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal study will evaluate the safety and efficacy of AVIM Therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted Breakthrough Device Designation by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.

Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the implementation and design of the BACKBEAT pivotal study, the potential efficacy and safety of the Company’s commercial product candidates, the ability of the Company’s partnerships to accelerate clinical development, and the Company’s late-stage development programs and strategic partnerships. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 31, 2025, as updated by any risk factors disclosed under the heading “Item 1A. Risk Factors” in the Company’s subsequently filed quarterly reports on Form 10-Q.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Investor Contact
Silas Newcomb
Orchestra BioMed
[email protected]

Media Contact
Kelsey Kirk-Ellis
Orchestra BioMed
[email protected]

October 09, 2025 08:00 ET

 | Source:

Rocket Doctor AI Inc.

Toronto, ON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) today announced that its wholly-owned digital health platform and marketplace, Rocket Doctor Inc., is receiving advisory services and funding of up to $75,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop secure communications functionality, and funding of up to $25,000 from the CanExport SMEs program to accelerate product innovation and U.S. market growth.

The NRC IRAP support will be dedicated to the development of a secure, PHIPA- and HIPAA-compliant messaging feature for Rocket Doctor’s care platform. This new capability will enable encrypted, real-time patient–clinician messaging for up to 5,000 concurrent users and a secure internal messaging system for over 500 clinicians. Designed to integrate seamlessly into Rocket Doctor’s workflows, the feature will align with Ontario Health’s Virtual Visit Solution standards, accelerate the company’s OTN certification timeline to Q1 2026, and position the platform for procurement by over 300 Ontario health service providers.

“This support enables us to accelerate development of secure, scalable communications technology that is essential for the future of healthcare,” said Dr. William Cherniak, Founder and CEO of Rocket Doctor Inc. “By ensuring our platform is fully compliant with PHIPA, HIPAA, and Ontario Health standards, we are not only serving Ontario patients, but also ensuring readiness across Canada, as well as for U.S. health systems, Medicaid / Medicare plans, and Commercial partners.”

Complementing this support is the CanExport contribution of $25,000 that will be used to accelerate Rocket Doctor’s U.S. expansion efforts, including the creation of professionally produced platform overview and case study videos, Spanish-language translation of its website and marketing materials, targeted online advertising in New York and California, and participation in key conferences to build partnerships with Medicaid managed care plans, hospitals, and Federally Qualified Health Centers (FQHCs).

These combined initiatives are expected to create new technical roles in Canada, enabling engineering resources to accelerate roadmap priorities, while increasing revenue potential through expanded eligibility for public procurement in Ontario and new deal flow in the United States. The secure-messaging platform enhancements will also increase adoption by equipping clinicians and patients with user-friendly communication tools that meet rigorous regulatory standards. Rocket Doctor’s growing software platform and expansion in the United States underscores its commitment to removing barriers to care, improving health equity, and leveraging Canadian innovation to solve cross-continental healthcare challenges.

About Rocket Doctor AI Inc.

Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.

Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 300 MDs to provide care to more than 700,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.

By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered.

To learn more about Rocket Doctor AI Inc’s products and services, contact:

www.rocketdoctor.ai  or email:

[email protected] Cautionary Statements

This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

October 09, 2025 08:00 ET

 | Source:

Bel Fuse Inc.

WEST ORANGE, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bel Fuse Inc. (Nasdaq: BELFA and BELFB), a designer, manufacturer, and provider of products that power, protect and connect electronic circuits, today announced plans to release preliminary financial results for the third quarter after market close on Wednesday, October 29, 2025. An earnings conference call has been scheduled as follows:

When:Thursday, October 30, 2025 at 8:30 a.m. ET  Dial in:877.407.0784, or international: 201.689.8560  Online:https://ir.belfuse.com/events-and-presentations  How:Live over the internet – Simply log on to the web at the address above  Replay:844.512.2921, or international: 412.317.6671   Conference ID: 13755990   A replay will be available after 12:30 p.m. ET for 30 days following the call.

About Bel
Bel (www.belfuse.com) designs, manufactures and markets a broad array of products that power, protect and connect electronic circuits. These products are primarily used in the defense, commercial aerospace, networking, telecommunications, computing, general industrial, high-speed data transmission, transportation and eMobility industries. Bel's product groups include Power Solutions and Protection (front-end, board-mount and industrial power products, module products and circuit protection), Connectivity Solutions (expanded beam fiber optic, copper-based, RF and RJ connectors and cable assemblies), and Magnetic Solutions (integrated connector modules, power transformers, power inductors and discrete components). The Company operates facilities around the world.

Contacts:

Bel Fuse Inc.
Lynn Hutkin, CFO
[email protected]

Three Part Advisors
Jean Marie Young, Managing Director
Steven Hooser, Partner
[email protected]
[email protected]

Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation

October 09, 2025 08:00 ET

 | Source:

Cidara Therapeutics, Inc.

SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for CD388 for prevention of influenza A and B in adults and adolescents who are at higher risk of influenza complications due to underlying immunodeficiency, are at higher risk of severe influenza despite influenza vaccination, or those for whom vaccines are contraindicated.

“This Breakthrough Therapy designation, in addition to the previously awarded Fast Track designation, underscores the importance of CD388 as a potential new non-vaccine prophylactic for seasonal influenza,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Individuals who have chronic medical conditions, advanced age, or are immune compromised may not be adequately protected by current vaccines, leaving them at higher risk for infection and complications from flu. As a long-acting prophylactic drug, CD388’s activity does not rely on an immune response, making it a potential prevention option for high-risk individuals as well as those for whom vaccines are contraindicated. We look forward to advancing CD388 through our ongoing Phase 3 ANCHOR trial and submission of a Biologic License Application.”

The Breakthrough Therapy designation is based on positive results from the Phase 2b NAVIGATE trial in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64. Top line data from the NAVIGATE study was announced in June 2025 and additional data will be presented at upcoming scientific conferences later in October.

A Phase 3 trial to evaluate the safety and efficacy of CD388, the ANCHOR Trial, was initiated at the end of September, six months ahead of schedule, in populations at high-risk for complications of influenza. Based on feedback from the FDA, the study population has been expanded to include generally healthy adults over 65 years old with no specific co-morbidities in addition to other high-risk populations with certain comorbidities and immune compromised status.

Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies. The benefits of Breakthrough Therapy designation include the eligibility for priority review, rolling submission of portions of the application, and FDA’s organizational commitment to involving senior management to provide guidance to the company to help determine the most efficient route to approval.

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “intends,” “believes,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to the potential benefits of and future plans for CD388, the expected timing, study design and target enrollment for the Phase 3 registrational trial of CD388, and the expected benefits of receiving a Breakthrough Therapy designation. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s clinical trials and other risks related to clinical development, delays in action by regulatory authorities, other obstacles associated with the enrollment of participants or other aspects of CD388 or other DFC development, having to use cash in ways other than as expected and other risks and uncertainties associated with Cidara’s business in general. These and other risks are identified under the caption “Risk Factors” in Cidara’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
[email protected]

October 09, 2025 08:00 ET

 | Source:

Gabelli Funds

GREENWICH, Conn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gabelli Funds will host its 49th Annual Automotive Symposium on November 3rd and 4th, 2025 at the Encore at Wynn in Las Vegas, Nevada.

This two-day symposium will feature presentations by senior management of leading automotive and trucking companies, with a lineup that allows investors to understand the ever-changing dynamics within the automotive industry. Discussions will cover a variety of topics, including the potential effect of tariffs, vehicle affordability, car complexity and the shift to autonomous vehicles, aftermarket resilience, and more. Attendees will also have the opportunity to meet with management in a one-on-one setting.

Presenting attendees, which include original equipment suppliers, automotive retailers, aftermarket service participants and next-gen tech companies driving vehicle electrification will provide a “cradle to grave” look at the automotive ecosystem and help investors understand “What’s Next?” for the automotive space.

Click here to view

Presenting Companies

Advance Auto Parts, Inc. (NYSE: AAP) Monro, Inc. (NASDAQ: MNRO)AutoNation, Inc. (NYSE: AN) Motorcar Parts of America, Inc. (NASDAQ: MPAA)AutoZone, Inc. (NYSE: AZO) MP Materials Corporation (NYSE: MP)Dana Incorporated (NYSE: DAN) NN, Inc. (NASDAQ: NNBR)Donaldson Company, Inc. (NYSE: DCI) O'Reilly Automotive Group, Inc. (NASDAQ: ORLY)Dorman Products, Inc. (NASDAQ: DORM) Penske Automotive Group, Inc. (NYSE: PAG)Experian PHINIA, Inc. (NYSE: PHIN)Garrett Motion Inc. (NASDAQ: GTX) Rush Enterprises, Inc. (NASDAQ: RUSHB)Gentex Corporation (NASDAQ: GNTX) Sonic Automotive, Inc. (NYSE: SAH)Genuine Parts Company (NYSE: GPC) Standard Motor Products, Inc. (NYSE: SMP)LKQ Corporation (NASDAQ: LKQ) Strattec Security Corporation (NASDAQ: STRT)    The Encore at Wynn, Las Vegas, NV
Monday, November 3rd and Tuesday, November 4th

Registration link: CLICK HERE

Research Team

Gabelli Funds, LLC is a registered investment adviser with the Securities and Exchange Commission and is a wholly owned subsidiary of GAMCO Investors, Inc.

Contact:Miles McQuillen
Private Wealth Management
(914) 921-5112 

October 09, 2025 08:00 ET

 | Source:

DIRTT Environmental Solutions

CALGARY, Alberta, Oct. 09, 2025 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (“DIRTT”, the “Company”, “we”, “our”, “us” or “ours”) (TSX: DRT; OTCQX: DRTTF), a leader in industrialized construction, today announced continued momentum in its commercial pipeline, marked by over $7 million in projects advancing across five clients. The contracts span multiple sectors, including healthcare, workplace, and aviation.

Among the new projects are The Hospitals of Providence in El Paso, Texas, valued at over $1.5 million, and The Ohio State University Wexner Medical Center Outpatient Care Powell, a $4.7 million project spanning 20 phases through April 2026. Together, these projects highlight DIRTT’s continued success in delivering scalable programs across major healthcare systems. Favorable market trends, reflected in a 33% increase in the Dodge Momentum Index year over year, signal expanding construction planning in key markets.

“Our recent project wins demonstrate the depth and strength of our client relationships,” said Benjamin Urban, CEO of DIRTT. “Growing momentum across multi-phase projects and repeat customers reflects confidence in DIRTT’s construction system while broader market indicators continue to show a positive outlook for growth.”

DIRTT’s 12-month forward pipeline has increased 1.2% from September 1, 2025 to October 1, 2025, indicating steady, sustained demand for its adaptable interior construction solutions.

ABOUT DIRTT

DIRTT is a leader in industrialized construction. DIRTT’s system of physical products and digital tools empowers organizations, together with construction and design leaders, to build high-performing, adaptable, interior environments. Operating in the workplace, healthcare, education, and public sector markets, DIRTT’s system provides total design freedom, and greater certainty in cost, schedule, and outcomes. DIRTT’s interior construction solutions are designed to be highly flexible and adaptable, enabling organizations to easily reconfigure their spaces as their needs evolve. Headquartered in Calgary, AB Canada, DIRTT trades on the TSX under the symbol “DRT” and on the OTCQX under the symbol "DRTTF".

Certain statements contained in this release are “forward-looking statements” within the meaning of “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 and “forward-looking information” within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact included in this news release are forward-looking statements. When used in this news release, the words “anticipate,” “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.

Forward-looking statements are based on certain estimates, beliefs, expectations, and assumptions made in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that may be appropriate. Forward-looking statements necessarily involve unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from those expressed or implied in such statements. Due to the risks, uncertainties, and assumptions inherent in forward-looking information, you should not place undue reliance on forward-looking statements. Factors that could have a material adverse effect on our business, financial condition, results of operations and growth prospects include, but are not limited to, risks described under the section titled “Risk Factors” in our Annual Reports, and in our subsequently filed Quarterly Reports on Form 10-Q and also in the Company’s other continuous disclosure filings available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Our past results of operations are not necessarily indicative of our future results. You should not rely on any forward-looking statements, which represent our beliefs, assumptions and estimates only as of the dates on which they were made, as predictions of future events. We undertake no obligation to update these forward-looking statements, even though circumstances may change in the future, except as required under applicable securities laws. We qualify all of our forward-looking statements by these cautionary statements.

Contact:
[email protected]

MANCHESTER, N.H., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Allegro MicroSystems, Inc. (Nasdaq: ALGM) today announced it plans to release financial results for its second quarter fiscal year 2026 prior to the market open on Thursday, October 30, 2025. Following the press release, Mike Doogue, President and Chief Executive Officer, and Derek D’Antilio, Executive Vice President and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time to discuss the Company’s results and business outlook.

Analysts and investors are invited to join the conference call using the following information:

Second Quarter Fiscal Year 2026 Earnings Conference Call
Date: Thursday, October 30, 2025
Time: 8:30 a.m. ET
Live Webcast Link: Click Here
Dial-in Participant Registration Link: Click Here

Advanced registration is required for dial-in participants. Please complete the linked registration form above to receive a dial-in number and dedicated PIN for accessing the conference call.

A live and archived audio webcast of the conference call will also be accessible for at least 90 days on the Company’s website at investors.allegromicro.com in the Events & Presentations section.

About Allegro MicroSystems

Allegro MicroSystems, Inc. is leveraging more than three decades of expertise in magnetic sensing and power ICs, to propel automotive, clean energy and industrial automation forward with solutions that enhance efficiency, performance and sustainability. Allegro’s commitment to quality drives transformation across industries, reinforcing our status as a pioneer in "automotive grade" technology and a partner in our customers' success. For additional information, please visit https://www.allegromicro.com.

Contact: Jalene Hoover
VP of IR & Corporate Communications
Phone: +1 512 751 6526
[email protected]

Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials

October 09, 2025 08:00 ET

 | Source:

vTv Therapeutics Inc.

HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognized leaders in endocrinology, diabetes research, clinical trial design, and regulatory science, will continue providing strategic guidance on the development of cadisegliatin, which is currently being investigated in Phase 3 clinical trials as an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D).

“We are honored to welcome such a distinguished group of clinicians and scientists to vTv’s Scientific Advisory Board,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. “Their collective experience in diabetes care, clinical research, and regulatory engagement will be invaluable as we advance cadisegliatin and work to bring meaningful innovation to people living with type 1 diabetes. We also thank those past members of our SAB whose contributions have helped us immeasurably over the past several years.”

The members of the Scientific Advisory Board include:

John Buse, MD, PhD is a Professor of Medicine at the University of North Carolina at Chapel Hill and former President of the American Diabetes Association. He brings expertise in clinical trial design, diabetes outcomes, and therapeutic guidelines.Alfonso Galderisi, MD, PhD is a pediatric endocrinologist and physician-scientist (Associate Professor) at Yale University who specializes in the metabolic physiology of preclinical type 1 diabetes.Mark Evans, MD is a Professor of Diabetic Medicine at the University of Cambridge, U.K. He is renowned for his work on hypoglycemia and contributions to the Hypo-RESOLVE consortium.Chantal Mathieu, MD, PhD is a Professor of Medicine at the University of Leuven, Belgium and global expert in diabetes care and guidelines (EASD, EUDF).Alexander (Zan) Fleming, MD is Executive Chairman of Kinexum. At the FDA, Dr. Fleming was responsible for therapeutic review of diabetes and other metabolic and endocrine disorders and is a recognized expert in regulatory strategy.Klara Klein, MD, PhD is an Assistant Professor at the University of North Carolina at Chapel Hill. She serves as a Principal Investigator for multiple vTv clinical trials and is an experienced investigator in type 1 diabetes therapeutics. The SAB will regularly provide input on clinical trial planning, study design, endpoints, regulatory strategy, and the development of the target product profile for cadisegliatin.

About Cadisegliatin

Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin, which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

About vTv Therapeutics

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
[email protected]

Media Contact
Caren Begun
TellMed Strategies
201-396‑8551
[email protected]

Calgary, Canada - October 9, 2025 – TheNewswire - SuperQ Quantum Computing Inc. (“SuperQ Quantum”, “SuperQ”, or the “Company”) (CSE: QBTQ; Frankfurt: 25X; OTCQB: QBTQF), a global leader in quantum and supercomputing, is pleased to announce that its CEO and Board Chair, Dr. Muhammad Khan, has been invited to speak at the upcoming Quantum Strategic Industry Alliance for Revolution (“Q-STAR”) meeting in Japan on October 14th, 2025 (October 15th, 2025 in Japan). Q-STAR was established in Japan in 2021 to create new industries and business opportunities based on quantum technology. Its 100-plus members come from various business sectors and includes major corporations like Fujitsu, Hitachi, NEC, NTT and Toshiba.

Presentation Details

Date / Time: October 14, 2025, 5:00 – 6:00 PM PT

Title: Quantum-Driven Autonomy and Disaster Resilience: Solutions for Japan’s Future

Abstract: Japan’s pressing societal challenges - including disaster response, sustainable agriculture, and resilient logistics - demand breakthrough solutions that transcend traditional approaches. Recently, SuperQ Quantum (CSE: QBTQ) has launched Super, a hybrid quantum and classical high-performance computing platform for solving optimization and cybersecurity problems, that has helped move several quantum-powered solutions from scientific theory to commercial reality in 2025. It particularly excels at producing hybrid quantum solutions for real-time route optimization, large-scale scheduling, autonomous fleet management, and dynamic supply chain efficiency. We will showcase live products and case studies, including coordination of robotic swarms in agriculture, quantum-enhanced evacuation routing, and enhancing the accuracy of AI models - illustrating how quantum computing uniquely accelerates safe, adaptive decision-making in complex environments. Drawing examples from SuperQ’s cross-sector achievements and global collaboration experiences, the presentation will highlight actionable partnership frameworks for Q-STAR members, including NEC, Toshiba, and Fujitsu, to co-create impactful pilots and scale quantum technologies for societal benefit. Attendees will learn how practical quantum solutions can fuel innovation, mitigate risk, and unlock new business opportunities for Japan’s quantum ecosystem.

“We are deeply honored to present to Q-STAR,” said Dr. Khan. “This is a prime opportunity to align SuperQ’s global experience with Japan’s industrial strengths, and to explore concrete collaborations that accelerate quantum adoption in mission-critical sectors.”

Strategic Significance of Engaging with Q-STAR

Q-STAR, founded in September 2021, and officially incorporated in May 2022 as a general incorporated association in Japan, is the country’s flagship industry alliance for quantum technology. Its mission is to catalyze new industries and business opportunities in Japan, grounded in quantum technology, through collaborations among corporations, start-ups, academia, and government.

The founding meeting included the who-is-who of Japan’s industry Titans such as Canon, Fujitsu, Hitachi, Mitsubishi Electric Corporation, Mitsui Sumitomo Insurance Company, Mizuho Financial Group, NEC, Nippon Telegraph and Telephone Corporation, Sumitomo Corporation, Toshiba, and Toyota Motor Corporation. With over 100 members, Q-STAR plays a central role in Japan’s national quantum agenda, forging industry–academia–government linkages, promoting standards and talent development, and enabling global collaboration.

Japan has been at the forefront of developing and adopting quantum technologies. SuperQ views this engagement as a catalyst to its growth in Asia and its entry point into Japan. Q-STAR is Japan’s focal alliance for quantum, uniting major industrial actors, academia, and government around common goals. By engaging directly with members such as NEC, Toshiba, and Fujitsu, SuperQ aims to explore joint pilot initiatives, bridge deployment pathways, and reinforce Japan’s global leadership in quantum applications.

About SuperQ Quantum Computing Inc.

SuperQ Quantum Computing Inc. (CSE: QBTQ; Frankfurt: 25X; OTCQB: QBTQF) is defining the next era of enterprise transformation, looking to emerge as a partner for global organizations seeking direct quantum and supercomputing ROI previously beyond reach.  We are looking to position ourselves as the trusted leader in quantum and supercomputing-powered problem-solving and optimization.

Our flagship Super™ platform strives to make the most advanced computational power intuitive and accessible. This will empower executives, leading research institutions, and critical government agencies to unlock immediate business impact across finance, healthcare, logistics, defense, and beyond, leveraging our proprietary AI Autopilots to turn complex challenges into executive-ready results with one-click productization and deployment. SuperQ Quantum is headquartered in Canada with a growing international presence, particularly in the US, Middle East and Asia, strategically establishing Super Hubs in key regions.

For further information contact:

Dr. Muhammad Khan, CEO of SuperQ Quantum Computing Inc.

Email: [email protected]

Telephone: +1 587 889 1918

www.superq.co          

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, or operations that is prospective in nature. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking information. Forward-looking information is often identified by terms such as “may”, “should”, “anticipate”, “would”, “will”, “estimates”, “believes”, “intends” “expects” and similar expressions which are intended to identify forward-looking information. More particularly and without limitation, this press release contains forward-looking information concerning statements with respect to future plans of the Company. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company, including but not limited to assumptions regarding prevailing market conditions and general business, economic, competitive, political and social uncertainties to develop the forward-looking information in this press release. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.

The forward-looking information contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

United Airlines' summer 2026 international travel plan is out, and smaller European cities are in.

Starting April 30, United plans to fly from its hub at Newark Liberty International Airport in New Jersey to Split on the Croatian coast — its second destination in the country. A day later the carrier is launching Newark to Bari in the popular Puglia region of southern Italy on the Adriatic Sea.

May 22 is the scheduled launch of a nonstop from Newark to Santiago de Compostela, in the Galicia region of Spain, the end of the famed Camino de Santiago pilgrimage trail.

The additions show United's latest bet on high-spending travelers looking for trips beyond major European capitals, and the chance to fly to those places nonstop, without connecting in big hubs. The carrier is vying with Delta for big-spending travelers. Most of the new routes are operated with airplanes outfitted with its ever-growing, lie-flat Polaris cabin.

United executives have long touted its vast international network as a driver for customer loyalty and sign-ups for lucrative travel rewards credit cards.

United's other additions include a May 21 debut from its Washington Dulles International Airport hub to Reykjavik, Iceland, and a daily, year-round nonstop from Newark to Seoul, South Korea, starting next September. It will also start a Newark to Glasgow, Scotland, flight on May 8, on a Boeing 737 Max 8.

Patrick Quayle, United's senior vice president of global network planning and alliances, said that destinations the carrier announced last year, including Nuuk, Greenland, will remain in the airline's schedule for 2026.

United is also planning to add a third daily flight to Tel Aviv from Newark starting March 28.

SummaryZenas BioPharma (ZBIO) secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology indications.ZBIO's two late-stage candidates, obexelimab and orelabrutinib, drive optimism, with topline Phase 3 INDIGO trial data for obexelimab expected in late 2025.Strong cash position and recent private placement provide operational runway through 4Q26, supporting ongoing clinical development and mitigating dilution risks.Despite high valuation multiples and competition, positive Phase 3 results could unlock significant upside, with key catalysts ahead in 2025 and 2026. XH4D/E+ via Getty Images

Thesis The biggest news this week has been Zenas BioPharma Inc.'s (NASDAQ:ZBIO) licensing agreement with InnoCare (OTCPK:INCPF). It's a deal tipped to be worth $2 billion, with Zenas gaining rights to the global market, only excluding China and Southeast

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Every now and then, a sector catches a tailwind so strong it lifts every name in the group, even the ones that don’t deserve it. That’s what’s been happening in natural resources this year. Oil and gas plays, miners, and energy infrastructure stocks have all enjoyed a run thanks to rising commodity prices and renewed investor appetite for “real assets.” But under the surface, not every name is pulling its weight.

Today’s Bear of the Day is Core Natural Resources ((CNR - Free Report) ), a stock that’s been lagging behind its peers despite the broader commodity rally. The company finds itself struggling with execution, inconsistent production volumes, and weakening profitability. That combination has analysts turning sour, and it’s showing up in the Zacks Rank. CNR currently carries a Zacks Rank #5 (Strong Sell).

The reason for the unfavorable Zacks Rank is the recent negative earnings revisions coming from analysts. Our current year Zacks Consensus Estimate has tumbled from $5.37 to a loss of $1.10. Looking at next year, earnings estimates are off from $12.24 to $10.39. Granted, that is a huge amount of earnings growth coming down the pike. However, that comes on revenue growth of just 6.3% next year. This is also a stock that has run up from under $70 to $97 in a little over a month.

Core Natural Resources’ biggest problem isn’t top-line growth, right now it’s profitability. The company has been facing higher input costs, operational inefficiencies, and tougher contract terms in several of its core basins. Add to that a debt load that’s creeping higher due to capital spending on new projects, and you get an ugly balance sheet picture. Debt-to-equity now sits at a multi-year high, pressuring cash flow and limiting flexibility.

When analysts are cutting estimates, margins are shrinking, and debt is climbing, that’s not a recipe for outperformance. Core Natural Resources finds itself on the wrong side of the commodity cycle at the worst possible time. Until the company can reverse the earnings revisions trend, investors may want to stay on the sidelines.

The Coal industry ranks in the Bottom 14% of our Zacks Industry Rank. There are no stocks within this industry that are in the good graces of our Zacks Rank. There are two Zacks Rank #3 (Hold) stocks. These include Alliance Resource Partners ((ARLP - Free Report) ) and SunCoke Energy ((SXC - Free Report) ).

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York. As a journalist, he has covered every futures market traded in the U.S., at one time or another.

Jim is the proprietor of the "Jim Wyckoff on the Markets" analytical, educational and trading advisory service. Jim also worked as a technical analyst for Dow Jones Newswires and as the senior market analyst with TraderPlanet.com. Jim is also a consultant with the highly respected "Pro Farmer" agricultural advisory service. Jim was also the head equities analyst at CapitalistEdge.com. He received his degree from Iowa State University in Ames, Iowa, where he studied journalism and economics.

Follow Jim daily on Kitco.com as he provides both AM and PM roundups and a daily Technical Special.
1 877 963-NEWS
jwyckoff at kitco.com

In brief
A Herzliya crypto trader was reportedly stabbed twice and robbed of nearly $600,000 in crypto after three assailants ambushed him in his apartment building on September 7.
The attack lasted over an hour, with captors allegedly threatening his family and cleaning the crime scene with disinfectant before fleeing with Bitcoin, USDT, and a $50,000 Rolex.
A security expert reported 52 such "wrench attacks" globally in 2025, averaging one per week.
A crypto trader in Herzliya was allegedly bound, beaten, and stabbed in his own home during a brutal robbery that netted thieves approximately $600,000 in crypto, the latest victim in what security analysts are calling a global wave of “wrench attacks” targeting crypto holders.

The Tel Aviv District Attorney's Office indicted Murad Mahajna of Tel Aviv this week for orchestrating the home invasion alongside two accomplices, according to a local media report.

According to prosecutors, the repeat offender with ten prior convictions discovered that the victim owned Bitcoin and planned the attack on the father of two, who lives with his wife and daughters.

The ordeal took place on September 7, when three suspects allegedly ambushed the victim in his building’s stairwell, with two masked assailants forcing him inside, binding his hands with cables, and brutally beating him.

"We came to take money, we are from the Karaja family," Mahajna, who was not wearing a mask, allegedly told the victim, while initially demanding 500 BTC worth approximately $61 million.

Prosecutors claim that when the victim refused to surrender his wallet credentials, one assailant grabbed a kitchen knife and held it to his neck as Mahajna warned, “Let me get you out of this incident alive,” before stabbing him twice, once in each leg above the knee.

The victim finally yielded access to his accounts, allowing the assailants over the next hour to transfer $547,260 in Bitcoin and $42,248 in USDT to their wallets. They also seized a $50,000 Rolex, a laptop, a Trezor hardware wallet, €5,000, and several thousand shekels in cash, prosecutors said.

Fearing for his family’s safety, the victim stayed silent for several days before confiding in relatives, who urged him to go to the police; investigators arrested Mahajna on September 10 using recorded calls, voice analysis, and security camera evidence.

Bitcoin “wrench attacks”So-called “wrench attacks” in which crypto holders are physically attacked are on the rise.

Security researcher Jameson Lopp, who maintains a database tracking these incidents, tweeted that at the start of the year he had predicted 2025 would be "an all-time high for wrench attacks and we'd average one per week," adding that the incident in Israel is the 52nd such attack of the year.

September alone saw four wrench attacks globally, according to Lopp's database.

“My advice is to obscure any physical data and conceal carry, and unfortunately, in most of the world, you can’t do the latter,” Mehow Pospieszalski, CEO of decentralized wallet platform AmericanFortress, told Decrypt.

He said that weak cooperation between the crypto community and authorities has worsened the situation, with “law enforcement not exactly proactive about protecting founders” and a “vibe of mistrust” from the crypto side that hinders the very coordination needed to catch such criminals.

Last month, French authorities deployed 150 gendarmes to rescue a 20-year-old Swiss man found tied up in a house near Valence's high-speed train station in one such wrench attack.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

12h05 ▪
4
min read ▪ by
Ifeoluwa O.

Summarize this article with:

BNB reached a new all-time high of $1,336, marking a record for the cryptocurrency. Following this achievement, YZi Labs, the venture capital firm founded by Changpeng ‘CZ’ Zhao, announced a $1 billion fund to support developers building projects within the BNB ecosystem.

In Brief

YZi Labs, founded by CZ, announced a $1 billion fund to support developers building on the BNB Chain.
The fund aims to accelerate projects across sectors including DeFi, AI, DeSci, trading, payments, wallets, and RWA.
Participants will gain access to YZi Labs’ global network of investors, mentors, partners, and a user base of over 460 million.

Expanding Support for BNB Builders
Formerly known as Binance Labs, YZi Labs said the fund is intended to deepen its commitment to the growth of projects built on the BNB Chain, with a focus on long-term innovation. The initiative targets emerging sectors such as “trading, RWA, AI, DeSci, DeFi, Payments, Wallets — leveraging the high-performance, low-cost infrastructure of BNB Chain as well as the enhanced tools, funding, integrations, and 460M+ user ecosystem.”

A central feature of this plan is the integration of the Most Valuable Builder (MVB) accelerator into YZi Labs’ EASY Residency beginning in October 2025. The merger will create a single program dedicated to builders within the BNB Chain environment. Selected participants will be able to receive as much as $500,000 in direct funding and will gain close access to the core development teams at both YZi Labs and BNB Chain.

Beyond funding, participants will be able to connect with YZi Labs’ global network of investors, mentors, and business partners, as well as tap into its ecosystem of over 460 million users.

Past Contributions of YZi Labs
YZi Labs has actively supported innovation and strengthened institutional participation in the BNB ecosystem through initiatives such as

Supporting notable projects including PancakeSwap, ListaDAO, Aster, and Aspecta, all of which originated from the MVB program.
Expanding institutional participation through initiatives such as the BNB Digital Asset Treasury (DAT) by BNC, the RWA fund by China Renaissance, and the BNB Yield Fund in partnership with Hash Global.
Organizing global events and gatherings in Seoul and Singapore to bring together developers, investors, and partners.

Ella Zhang, Head of YZi Labs, described the blockchain ecosystem as “the next phase of digital infrastructure, where decentralization, on-chain scalability converges with security and real distribution.” She added that  “Through this $1B BNB Builder Fund, YZi Labs is committed to supporting BNB builders  across sectors such as DeFi, AI, RWA, DeSci, and more — those building the next generation of open systems that connect technology back to human progress.”

Record High for BNB and Impact on CZ’s Holdings
The announcement came at a particularly strong moment for BNB, which reached a new record on October 7. The cryptocurrency has solidified its position as the third-largest digital asset by market capitalization, surpassing Ripple’s XRP, with a total value of $182 billion. 

BNB has risen more than 27% over the past seven days and over 49% in the past month, along with a modest 1% increase in the last 24 hours. The surge has also led to a considerable increase in CZ’s holdings. As of June 2024, he reportedly owned around 64% of the total BNB supply, which, at the current valuation, is estimated to be worth approximately $116 billion.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Join the program

A

A

Lien copié

Ifeoluwa O.

Ifeoluwa specializes in Web3 writing and marketing, with over 5 years of experience creating insightful and strategic content. Beyond this, he trades crypto and is skilled at conducting technical, fundamental, and on-chain analyses.

DISCLAIMER

The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.

Story HighlightsThe live price of Bitcoin Cash is  $ 574.16716103Price predictions for 2025 range from $300 to $710, with strong support at $300.By 2030, BCH could reach highs of $2,675, driven by increased adoption and transaction activity.With Bitcoin smashing through the $100K barrier, all eyes are now on Bitcoin Cash (BCH) as traders wonder—will BCH price follow with a banana move of its own? Beyond hype, Bitcoin Cash is proving its value in the real world. Ranked 4th on Crypwerk’s global adoption list, BCH is gaining traction for its speed, low fees, and merchant-friendly design. 

If you’re searching for answers to “Will Bitcoin Cash go up further?” — you’re not alone. In this Bitcoin Cash price prediction 2025–2030, we dive into the technicals and adoption trends shaping the next big BCH Price Prediction.

CryptocurrencyBitcoin CashTokenBCHPrice$574.1672 -0.94% Market Cap$ 11,446,924,874.2224h Volume$ 283,442,064.2529Circulating Supply19,936,571.8750Total Supply19,936,571.8750All-Time High$ 4,355.6201 on 20 December 2017All-Time Low$ 75.0753 on 15 December 2018CoinPedia’s Bitcoin Cash Price PredictionCoinpedia’s analysis suggests that Bitcoin Cash could potentially emerge as a more affordable version of Bitcoin. 

If Bitcoin Cash gains some hype in the coming months, then the BCH price can reach $701 in 2025. On the flip side, the BCH price can drop to $507 during that year.

We expect the BCH price to create a new 2025 high of $701 during the upcoming altcoin season.  

YearPotential LowPotential AveragePotential High2025$507$605$701Bitcoin Cash Price Target October 2025Bitcoin Cash (BCH) consolidated in September and October after bouncing from $522 and testing $640. The remaining days of October are critical.

Bullish: Flipping the $620–$640 zone into support unlocks $689 and further upside next month.

Bearish: A drop below $550 sends the price back to the $522 support, which must hold to prevent a deeper correction.

MonthPotential Low ($)Potential Average ($)Potential High ($)Bitcoin Cash Price October 2025422522689BCH Price Prediction 2025Bitcoin Cash (BCH) is exhibiting a major shift in its long-term trend after successfully breaking a multi-year resistance line, a line that had historically triggered bearish reversals in past bull markets. The powerful rally from April in 2025, fueled by market optimism, propelled BCH from $249 to a high of $640 in August.

This surge has produced consecutive bullish monthly candles, confirming a definitive breakout from a long-term descending triangle pattern on the monthly (1-M) chart. This breakout suggests the potential for a much larger rally, possibly revisiting previous all-time highs could be getting ready.

While the price briefly touched the $620–$640 range in mid-August, it closed the month at a key support of $522. Consolidation in the $530–$630 range has dominated September and October, making the upper bound of this range crucial for the next phase.

Bullish Case: A sustained daily close above the $620–$640 range will trigger an imminent retest of $689. Successfully holding above $689 would establish a “Change of Character (ChoCh)” on the monthly chart, officially signaling a major long-term trend shift. Continued momentum could realistically target $800, $950, $1200, and $1600 before year-end.

Bearish Case: A failure of the breakout thesis would see the price drop. If BCH loses critical support levels at $522 and $422, the $300 level is expected to act as a strong buffer against a further severe decline.

YearPotential LowPotential AveragePotential High2025$300$605$1200Bitcoin Cash Price Targets 2026 – 2030YearPotential Low ($)Potential Average ($)Potential High ($)202659579098520276809251,16020287951,1351,47520291,0251,4801,95520301,3502,0102,675This table, based on historical movements, shows BCH price to reach $2675 by 2030 based on compounding market cap each year. This table provides a framework for understanding the potential BCH price movements. Yet, the actual price will depend on a combination of market dynamics, investor behavior, and external factors influencing the cryptocurrency landscape.

Market AnalysisFirm Name2025020262030Changelly$361$664$3731priceprediction.net$572$865$3830DigitalCoinPrice$821$932$2912*The targets mentioned above are the average targets set by the respective firms.

Never Miss a Beat in the Crypto World!Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

FAQsWhat could be the maximum price of BCH in the next 3 years?

According to our Bitcoin Cash price prediction, BCH’s price could hit the maximum trade value of $1,160 by 2027.

What Is Bitcoin Cash?

Bitcoin Cash is a hard fork of Bitcoin, that aims at a decentralized peer-to-peer electronic cash system. Without relying on any central governing authority.

Is Bitcoin Cash a good investment in 2025 amidst newer higher-performing entrants?

Bitcoin Cash is an underrated investment with a high chance of performing in 2025.

What are the advantages of Bitcoin Cash over Bitcoin?

Bitcoin Cash focuses on resolving two of the major limitations of Bitcoin, which are scalability and transaction fees.

BCHBINANCE Disclaimer and Risk WarningThe price predictions in this article are based on the author's personal analysis and opinions. CoinPedia does not endorse or guarantee these views. Investors should conduct independent research before making any financial decisions.

ETH price has formed a highly bullish continuation pattern, a confirmed breakout above which could potentially push the token to a new all-time high in the coming months.

Summary

ETH price is down roughly 9% after failing to breach the $4,700 resistance earlier this week.
A multi-month bull flag pattern has formed on the weekly chart.

According to data from crypto.news, Ethereum (ETH) price fell 4% to an intraday low of $4,329 on Oct. 9 afternoon Asian time after bulls failed to breach the $4,600 resistance level late last night. At its current price, the token is down approximately 9% from its weekly high of $4,753, reached on Tuesday on the back of project-specific catalysts and a broader market rally sparked by renewed optimism across the crypto space.

The rally was fueled in part by the historically bullish sentiment that surrounds October, a month known for strong seasonal gains for cryptocurrencies. Strong inflows into spot Ethereum ETFs and macro tailwinds, such as expectations of dovish central bank policies, also contributed to the upbeat momentum.

However, the tide began to shift on Oct. 7, as Ethereum failed to break past the $4,700 resistance level for the second time over the past 30 days. The pullback was triggered by a combination of profit-taking by short-term traders, broad-based market liquidations, and a resurgent U.S. dollar, all of which weighed on investor sentiment and put downward pressure on ETH’s price.

As ETH price continued to slide downward following the recent rejection at higher levels, it has now formed a giant bullish flag pattern on the weekly chart. In technical analysis, this pattern emerges when an asset’s price rallies sharply and then consolidates in a downward-sloping channel, often signaling a pause before the next leg higher.

ETH price has formed a giant bullish continuation pattern on the weekly chart — Oct. 9 | Source: crypto.news
At press time, ETH was also trading above all key simple moving averages on the weekly chart, with the shorter-term SMAs still crossing above the longer ones, a classic bullish alignment that suggests continued strength and buyer control.

Meanwhile, momentum indicator RSI showed a reading of 61, which means that ETH still has room to run before it enters overbought territory, giving bulls more breathing space before any serious correction kicks in.

Zooming into the daily timeframe, the price action has also confirmed a golden cross, with the 50-day moving average crossing above the 200-day. The pattern is typically associated with long-term bullish momentum and historically followed by sustained price rallies.

ETH price action confirmed a golden cross on the daily chart — Oct. 9 | Source: crypto.news
For now, the key resistance level for the ETH price stands at $4,500, which marks a psychological barrier and aligns with the upper boundary of the bull flag pattern. 

A clean breakout above this zone could confirm the pattern and reignite ETH’s uptrend, initially toward $5,000, and potentially even toward the measured move target of $8,100, calculated by adding the height of the flagpole to the breakout point.

However, some market watchers urge caution, now that ETH has slipped close to a major support area. According to well-followed analyst Ted Pillows, Ethereum must hold the $4,250–$4,300 support zone to maintain its bullish setup. 

A decisive break below that range could invalidate the pattern, opening the doors for a deeper correction toward $4,000 in the coming weeks

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Ethereum could peak between $8,500 and $12,200 if historical trends repeat in 2025.Key metrics like the 200-week average and realized price support ongoing ETH strength.Institutional inflows and macro ratios support optimism, but volatility risks persist.Ethereum’s price may reach new all-time highs by late 2025, with analysts projecting a potential cycle top between $8,500 and $12,200.

While historical data anchored to technical, on-chain, and institutional indicators support the case for a significant price surge, volatility remains a key risk.

Sponsored

Sponsored

Major Indicators Signal Elevated ETH Price TargetsEthereum was trading for $4,450 as of this writing, up by a modest 0.5% in the last 24 hours. The largest altcoin by market cap metrics approaches important bull market thresholds.

Ethereum (ETH) Price Performance. Source: BeInCryptoAgainst this backdrop, analysts are closely monitoring key market metrics. Reports from industry leaders indicate that price targets between $8,500 and $12,000 are possible if current trends hold and investor sentiment stays bullish.

These projections rely on established metrics such as the 200-week moving average and realized price, which offer benchmarks for ETH in the current cycle.

The 200-week moving average (WMA) is a widely used barometer for market cycles. Currently, Ethereum trades about 92% above its 200WMA of roughly $2,400, a setup echoing the beginning of the 2021 rally.

During that cycle, ETH peaked at 492% above its 200WMA. If Ethereum repeats a similar performance and climbs 400% above this average, its price could hit $12,200.

Ethereum (ETH) Price Performance. Source: TradingViewSponsored

Sponsored

However, more cautious models suggest a peak between $7,300 and $11,000 if ETH trades 200–350% over the 200WMA. These outcomes reflect historical patterns and detailed research from sources like The DeFi Report and prominent on-chain analytics platforms.

Michael Nadeau, the founder of the DeFi Report shared 5 scenarios for ETH price action:

1. If ETH trades 200% above its 200 WMA: $7.3k ETH
2. If ETH trades 250% above its 200 WMA: $8.5k ETH
3. If ETH trades 300% above its 200 WMA
4. If ETH trades 350% above its 200 WMA
5. If ETH trades 400% above its 200 WMA: $12.2k ETH
This aligns with a recent Standard Chartered prediction, which forecasted a $7,500 price target for the Ethereum price.

Additional market indicators reinforce these bullish projections. The realized price, a marker for the average price at which all ETH was last moved, has climbed above $4,000 in 2025.

Sponsored

Sponsored

Ethereum Realized Price. Source: TradingViewThis aligns with scenario analysis that places potential cycle tops in the $8,700 to $11,600 range, depending on realized price conditions at the peak.

Institutional Flows and Macro Correlations Add ConfidenceMeanwhile, institutional participation in Ethereum is at record levels, bolstering confidence in a sustained rally. Regulatory filings show strong fund inflows, with significant institutional exposure such as the iShares Ethereum Trust ETF, which reported over $4.4 billion in assets as of June 2025.

A 2025 survey from Ernst & Young found that most institutional investors believe in Ethereum’s staying power this cycle. This is attributed to regulated investment vehicles and improved risk management practices.

Macro market ratios further frame Ethereum’s growth potential. In 2021, Ethereum’s market cap reached 55% of Bitcoin’s. Should Bitcoin reach $150,000, and Ethereum repeat this ratio, ETH could approach $13,500.

Sponsored

Sponsored

Analysts also track the ETH-to-Nasdaq ratio; a return to historic highs in this metric would put Ethereum’s price between $6,000 and $9,500. Together, these comparisons present scenarios where fundamentals and market activity align for a higher cycle top.

Caution: Cycle Peaks Are Historically VolatileWhile bullish sentiment dominates outlooks for Ethereum, crypto cycles are often marked by rapid reversals. Reports from major analytics sources, such as Glassnode and Binance, emphasize that long-term support and resistance levels should be viewed as reference points, not guarantees. Investors should therefore conduct their own research.

Volatility remains high in 2025, and history shows that cycle tops may be followed by severe corrections, sometimes exceeding 80%. Thus, both risk management and measured optimism are crucial for investors.

Understanding how diverse on-chain metrics, price averages, and macro ratios interact can help Ethereum holders navigate volatility.

If historical patterns repeat, the next quarter may define this bull cycle’s final phase, presenting both opportunities and risks as the market advances through 2025.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

The Ocean Protocol Foundation has resigned as a member of the Artificial Superintelligence Alliance, "effective immediately."

TLDR:

Ripple joined forces with Bahrain Fintech Bay to drive blockchain and digital asset innovation in the Kingdom.
The deal expands Ripple’s regional presence after securing a Dubai Financial Services Authority license in 2025.
The partnership will enable proof-of-concept projects, education, and local fintech collaborations in Bahrain.
Ripple aims to introduce its RLUSD stablecoin and custody solutions to Bahrain’s financial institutions.

Ripple is deepening its roots in the Middle East with a new strategic partnership in Bahrain. The company, known for providing digital asset infrastructure to global financial institutions, has teamed up with Bahrain Fintech Bay, one of the Kingdom’s leading innovation hubs. 

The move comes after Ripple secured a regulatory license from the Dubai Financial Services Authority earlier this year. It marks another milestone in Ripple’s regional expansion as it works to establish a stronger presence across the Gulf.

The collaboration focuses on supporting blockchain adoption and fintech development within Bahrain’s growing digital economy. 

Ripple and Bahrain Fintech Bay plan to work together on real-world projects that push forward the country’s blockchain readiness. The partnership also aims to connect local fintechs with Ripple’s global expertise to nurture innovation.

Blockchain Collaboration Aims to Boost Bahrain’s Fintech Growth
According to a press release from Ripple, the partnership will include developing pilot projects and proof-of-concept initiatives across several sectors. These will involve blockchain-based solutions for cross-border payments, digital assets, and tokenization. 

Ripple and Bahrain Fintech Bay also plan to collaborate on training programs and local accelerator initiatives to support talent development.

Reece Merrick, Ripple’s Managing Director for the Middle East and Africa, said the Kingdom had been one of the first to regulate crypto assets. 

He noted that Ripple looks forward to offering its custody platform and Ripple USD (RLUSD) stablecoin to local banks once frameworks allow. His remarks underline the company’s intention to become a long-term player in the region’s evolving financial ecosystem.

Suzy Al Zeerah, Bahrain Fintech Bay’s Chief Operating Officer, described the alliance as a bridge between global blockchain innovators and Bahrain’s local market. She added that the effort will enhance fintech innovation and support the creation of new financial solutions within the country’s ecosystem.

Ripple Strengthens MENA Presence Through Bahrain Entry
The expansion into Bahrain adds to Ripple’s growing portfolio of partnerships across the Middle East and North Africa. The company now holds more than 60 regulatory approvals globally, including the Dubai Financial Services Authority license secured in March 2025. 

Ripple’s involvement in regional fintech events like Fintech Forward 2025 further reflects its increasing engagement with local regulators and banks.

The partnership positions Ripple as a key contributor to Bahrain’s vision of becoming a blockchain and fintech hub in the Gulf. Through collaboration, infrastructure development, and education, Ripple aims to help advance financial innovation across the region.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Flare Network has recorded over $43 million worth of XRP now bridged onto its blockchain. This comes as a crypto expert predicts a potential breakout that could push the token toward a new all-time high (ATH).

Flare Network’s Hit Liquidity Milestone
In a recent X post, Flare Network co-founder Hugo Philion confirmed that the network now hosts $43 million in bridged XRP.

The assets were used to mint FXRP, a wrapped version of the altcoin native to the Flare blockchain. Users can engage in activities like lending and yield generation with the token without having to sell their primary holdings.

This milestone follows the launch of Flare’s stablecoin backed by XRP via Enosys Liquity V2.  For DeFi protocols developed on the network, the stablecoin offers deeper liquidity and improves capital efficiency.  Wrapped Flare (wFLR) is used as collateral for the stablecoin, increasing its on-chain usefulness.

The stablecoin product came after Flare Network rolled out Firelight. It is an institutional-grade product designed to deploy billions of XRP on the network. Firelight helps investors earn yield by using a liquid staking system.

Furthermore, the network reported that more than 15 million tokens are currently in motion on its network. This suggests that users experimenting with the FXRP model are adopting it more frequently.

15,000,000 XRP on Flare – in motion.

The XRPFi flywheel is just getting started pic.twitter.com/CFLdTveWZv

— Flare ☀️ (@FlareNetworks) October 9, 2025

Data from Dune Analytics further shows that demand for FXRP is increasing. Daily transactions and wallet interactions have been rising steadily since the feature launched.

Source: Dune
Expert Sees XRP Rally Toward New Highs
The strong on-chain activity has sparked bullish predictions from analysts. Prominent expert EGRAG CRYPTO described the current market structure for the token as “super bullish.” 

Source: X
The expert also noted that the asset remains technically sound above the $2.77 mark. He argued that short-term volatility is merely “noise” ahead of a major upward move. EGRAG predicted that the token might soon break through its past high to reach a new all-time high (ATH). 

He noted that increased investment from institutions could lead to a lasting price rise when the market conditions are right.

Adding to the bullish backdrop, institutional interest in the altcoin continues to rise. Recently, Reliance Global Group added XRP tokens worth $17 million to its digital asset collection. This purchase shows a trend of companies diversifying by holding this token. 

Additionally, there is growing excitement as the U.S. SEC is set to review several applications for XRP ETFs in October. Approval could make the altcoin the third significant cryptocurrency to obtain U.S.-listed ETF status, with companies like Greyscale, Bitwise, and WisdomTree among the applicants.

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.

SEC filing reveals ETH and SOL ETFs may include staking rewards Andjela Radmilac · 5 seconds ago · 2 min read

Bitwise and 21Shares quietly added language to their updated S-1s allowing staking, a move that could reshape how crypto ETFs generate yield if approved.

Oct. 9, 2025 at 11:44 am UTC

2 min read

Updated: Oct. 9, 2025 at 11:44 am UTC

Cover art/illustration via CryptoSlate. Image includes combined content which may include AI-generated content.

Two of the largest digital asset managers, Bitwise and 21Shares, have made a notable update to their Ethereum and Solana ETF filings that could signal a shift in how crypto exchange-traded products operate in the United States.

According to amended S-1 statements filed with the U.S. Securities and Exchange Commission (SEC), both issuers now reference the possibility of staking Ethereum and Solana holdings within their funds.

If approved, this change would allow these ETFs to earn staking rewards, the income generated by helping validate transactions on proof-of-stake blockchains. Until now, U.S.-listed crypto ETFs have been limited to holding underlying assets passively, without the ability to participate in network consensus.

The amended filings, submitted this week, come after several months of quiet lobbying from ETF issuers seeking regulatory clarity around staking income. While the inclusion of this language does not mean the SEC has approved the feature, it indicates that the agency is at least considering the idea.

Analysts view this as an early sign that the SEC’s stance on staking may be softening, especially given the growing pressure to allow ETFs to compete with on-chain yield opportunities available to retail and institutional investors abroad.

What staking inside an ETF could mean for ETH and SOL yieldsFor Ethereum, current staking rewards range between 3% and 4%, while Solana’s rewards typically fall between 7% and 8% annually. ETF management fees for these funds are generally around 0.20% to 0.30%, meaning that if staking proceeds are distributed to holders, the yield could cover or even exceed the fund’s fees.

Such a change could transform how ETF issuers compete in the market. Instead of focusing solely on management costs and liquidity, future funds may also compete on net yield, creating a new performance metric for investors comparing crypto ETFs.

While the SEC has not yet commented on these amendments, the filings suggest that staking could soon move from the on-chain economy into traditional financial products, bridging a gap between DeFi incentives and regulated investment vehicles.

Mentioned in this articleLatest US StoriesLatest Ethereum Stories

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The 100-day EMA, which has frequently served as the boundary between recovery and decline, is one of XRP’s most significant technical levels of 2025, and it has now been officially broken through.

XRP in troubleA decline toward $2.50 in the near future may be accelerated by the breakdown, which indicates that XRP is having difficulty finding any significant support. XRP has lost about 3% in the past day, wiping out several days of gains, and is currently trading at about $2.179.

XRP/USDT Chart by TradingViewA structural shift in sentiment is reflected in the move below the 100 EMA (orange line on the chart), which is more than just a temporary correction. Throughout Q4, the 100 EMA served as a dynamic support level, enabling XRP to hold onto its range in spite of macro uncertainty. The technical outlook is now firmly bearish after it was lost.

HOT Stories

The 200-day EMA, which has historically been a powerful defensive zone for XRP, is located close to $2.64, the next significant support. The path of least resistance, however, points downward as volume tapers off and momentum indicators like the RSI drift below 45. A retest of $2.50 appears not only feasible but also more likely if the price is unable to hold above $2.64.

XRP stepping downThe fact that XRP keeps printing lower highs within a larger descending triangle pattern, indicating ongoing weakness, adds to the pressure. The market’s skepticism regarding the token’s short-term potential is strengthened by each unsuccessful rebound, and traders are now watching the $2.50 zone as the final possible pivot point before a more significant correction occurs.

It is unlikely that the market will experience a sustained bullish reversal this quarter unless XRP can swiftly regain the 100 EMA and set new higher lows. The technical structure indicates that XRP is approaching a vulnerable phase, which could reshape its trajectory for the rest of 2025, as momentum is waning and no obvious catalyst is in sight.

XRP has once again found itself at the center of bullish predictions, with prominent crypto analyst Dark Defender believes the token is setting up for a massive breakout, just like it did in 2017 before prices exploded. 

By looking at XRP’s chart patterns, he suggests the coin could target between $6 and $7 if it keeps its momentum alive.

XRP’s 2017 Impulsive WaveDark Defender began with XRP’s historic 2017 rally, he notes that it followed a clear impulsive wave pattern that pushed prices to all-time highs $3.4. 

Meanwhile, Momentum indicators like the Relative Strength Index (RSI) showed strong upward force, while XRP consistently traded above the Ichimoku Clouds, a sign of heavy bullish control. Even technical corrections formed healthy patterns that paved the way for higher gains.

2021 The Correction Phase For XRPHowever, the 2021 cycle was far weaker. Dark Defender noted that XRP’s rally was a corrective structure following the 2018 crash. The RSI showed fading strength, XRP struggled below the Ichimoku Clouds, and candles never managed to break decisively above key resistance levels of $1.96.

Adding to the pressure, Ripple’s ongoing lawsuit with the SEC created uncertainty, keeping XRP from repeating its previous success.

Source : Dark Defender X postWhy 2025 Feels DifferentAs of now, Dark Defender says XRP is showing strong bullish signs again, trading above both the Ichimoku Clouds and Exponential Moving Averages. Meanwhile, RSI momentum now mirrors the strength seen in 2017, not the weakness of 2021.

According to the analyst, XRP’s recent breakout could be the start of a larger move. If the momentum continues, he expects XRP to target between $6 and $7 in the coming months.

Dark Defender ended by reaffirming his optimism, saying XRP and the broader crypto market are entering “a new era” of growth.

Never Miss a Beat in the Crypto World!Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

FAQsHow much will XRP reach in 2025?

Analyst Dark Defender predicts XRP could hit $6 to $7 in 2025, driven by strong bullish signals like trading above Ichimoku Clouds and robust RSI momentum.

How much will 1 XRP be worth in 2030?

Based on compounding growth and adoption, projections estimate XRP could trade around $26.50 by 2030, with averages near $19.75.

Can XRP make you a millionaire?

Hypothetically, yes—if XRP reaches $500+ and an investor holds a significant amount (e.g., 2,000 XRP). However, this is speculative and depends on extreme long-term growth.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.